Browse Category

NASDAQ:INBS 31 December 2025 - 2 January 2026

INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

INBS stock drops today as Intelligent Bio Solutions’ $10M private placement puts dilution in focus

Intelligent Bio Solutions shares fell 12.1% to $8.38 in late morning trading after announcing a $10 million private placement with two tranches of warrants. The deal, priced at $4.35 per share and warrant, follows a manufacturing partnership with Syrma Johari MedTech aimed at cutting costs and boosting margins ahead of a planned 2026 U.S. launch.
INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

Intelligent Bio Solutions shares jumped 132% to $9.53 before dropping 14% after-hours as the company announced a $10 million private placement and a new manufacturing deal with Syrma Johari MedTech. The placement, priced at $4.35 per share and warrants, is set well below the closing price. Volume hit 108 million shares. The company recently enacted a 1-for-10 reverse split after a Nasdaq minimum bid warning.
INBS stock jumps on Syrma Johari deal: Intelligent Bio Solutions targets 40% cost cuts

INBS stock jumps on Syrma Johari deal: Intelligent Bio Solutions targets 40% cost cuts

Intelligent Bio Solutions shares surged 132% to $9.53 Wednesday after announcing a manufacturing deal with Syrma Johari MedTech, targeting over 40% production cost savings and a 20-point gross margin boost. The stock slipped 6% to $8.95 after hours. The company remains under Nasdaq bid-price deficiency notice despite the rally. Market cap stood near $9 million at the close.
31 December 2025
INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

Intelligent Bio Solutions shares jumped 160% to $10.66 after announcing a manufacturing deal with Syrma Johari MedTech to scale production of its fingerprint drug-screening device. The company expects over 40% annual production cost savings and a 20-point gross margin boost. Trading volume hit 48.13 million shares, far above average. The stock traded between $5.62 and $11.52 after closing at $4.10 Tuesday.
Go toTop